Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Total Current Liabilities: 2022-2024

Historic Total Current Liabilities for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $106.9 million.

  • NewAmsterdam Pharma Co N.V's Total Current Liabilities rose 41.25% to $58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.3 million, marking a year-over-year increase of 41.25%. This contributed to the annual value of $106.9 million for FY2024, which is 114.28% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Total Current Liabilities stood at $106.9 million for FY2024, which was up 114.28% from $49.9 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's Total Current Liabilities' 5-year high stood at $106.9 million during FY2024, with a 5-year trough of $36.1 million in FY2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $49.9 million (2023), whereas its average is $64.3 million.
  • Data for NewAmsterdam Pharma Co N.V's Total Current Liabilities shows a peak YoY skyrocketed of 114.28% (in 2024) over the last 5 years.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Total Current Liabilities (Yearly) stood at $36.1 million in 2022, then skyrocketed by 38.38% to $49.9 million in 2023, then skyrocketed by 114.28% to $106.9 million in 2024.